Literature DB >> 1541606

Organic mental disorders associated with bupropion in three patients.

D Ames1, W C Wirshing, M P Szuba.   

Abstract

Bupropion hydrochloride is a phenylaminoketone antidepressant whose clinical pharmacology is poorly understood. Part of bupropion's action may be attributed to inhibition of dopamine reuptake that may induce organic mental disorders in certain susceptible patients. We report three cases of organic mental disorders in patients receiving bupropion hydrochloride for treatment of the depressed phase of their bipolar-type mood instability. The organic mental disorders that occurred in these patients were characterized largely by visual disturbances--visual hallucinations and visual illusions--although one patient also experienced auditory hallucinations. The patients' use of concomitant medications and potential drug interactions are carefully evaluated and the literature on bupropion's ability to induce organic mental disorders is reviewed. We suggest a number of possible mediating mechanisms for these syndromes including dose-related dopaminergic augmentation, accumulation of toxic metabolites, predisposition to psychosis, and drug interactions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541606

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge.

Authors:  Hervé Javelot; Alexandre Baratta; Luisa Weiner; Thierry Javelot; Cathy Nonnenmacher; Jean-Frédéric Westphal; Michaël Messaoudi
Journal:  Pharm World Sci       Date:  2008-11-28

3.  Can bupropion unmask psychosis.

Authors:  Sandeep Grover; Partha Pratim Das
Journal:  Indian J Psychiatry       Date:  2009-01       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.